Daily BriefsEquity Bottom-Up

Daily Brief Equity Bottom-Up: Adobe 2Q’23 Update and more

In today’s briefing:

  • Adobe 2Q’23 Update
  • Uchi Technologies (UCHI MK): Coffee and Cash Machine
  • Gap Trades of Small Cap Korean Pref Vs Common Shares
  • Nio Ends Holdout in China’s Auto Price War
  • Apple (AAPL) – The Big Apple = Most Valuable Company on Planet Earth
  • ECVT: Red Devil in the Details
  • Immix Biopharma – ATM completion may extend runway into H224
  • Kimberly-Clark: Short-Term Tailwinds, But Little Hope For The Long Run
  • Applied Materials Inc.: Launch of New R&D Facility & Other Drivers
  • Marvell Technology Inc.: Launch Of Silicon Interconnects A Possible Game Changer? – Key Drivers


Adobe 2Q’23 Update

By MBI Deep Dives

  • Revenue: Digital Media net new ARR $470 Mn ($50 mn higher than guide).
  • Gross Margin: Digital Media gross margin remains steady at ~96%, but Digital Experience posted its highest ever gross margin of 67.3% in 2Q’23.

  • Cost Structure: 2Q’23 GAAP operating margin was 33.7%, down from 34.9% in 2Q’22.


Uchi Technologies (UCHI MK): Coffee and Cash Machine

By Sameer Taneja

  • Uchi Technologies (UCHI MK), a manufacturer of controllers for coffee machines, has a 23-year track record of operating margins of over 40% and ROCEs of over 20%.  
  • Trading at 11.9x trailing PE, with a dividend yield of 9%, and 15% of the market cap in cash, the company has been serially paying dividends (payout > 70%). 
  • In its 2022 annual report, for the first time in its history, the company mentioned it has exciting growth plans that will be revealed over the year. 

Gap Trades of Small Cap Korean Pref Vs Common Shares

By Douglas Kim

  • In this insight, we provide gap trade opportunities among 30 small cap Korean preferred stocks with market cap of less than 100 billion won and more than 20 billion won.
  • Among these 30 companies, there are some in interesting gap trade opportunities, especially among those with relatively high dividend yields (more than 5%).
  • We have ranked these 30 stocks in terms of three criteria including market cap, pref/common share price ratio, and dividend yields. 

Nio Ends Holdout in China’s Auto Price War

By Caixin Global

  • Electric-vehicle maker Nio Inc. ended its holdout in China’s car price war and slashed base prices on all of its vehicles by 30,000 yuan ($4,200) in hopes of bolstering sales amid escalating competition in China, the world’s largest auto market.
  • Nio also pulled the plug on its free battery-exchange service for car buyers and introduced a pay-as-you-go system and a 30,000 yuan lifetime swap service.
  • The vehicle price cuts announced Monday will reduce the starting price of Nio’s new electric SUV ES6 to 338,000 yuan. The price of the mid-size electric sedan model ET5 will be lowered to 298,000 yuan. The changes take effect immediately, Nio said.

Apple (AAPL) – The Big Apple = Most Valuable Company on Planet Earth

By Maverick Equity Research

  • First of all, Apple is the most valuable company on the planet with a $2.8 trillion market capitalisation and eying for the whooping $3 trillion: +41% in 2023 alone.
  • And that equates to a total return in the last 10 years of a whooping 1,266%! Note also it was not a smooth run with some big drawdowns which even they had: 2016: 32%, 2019: 39%
  • Key take-away: business ownership vs stock ticker mentality is key …

ECVT: Red Devil in the Details

By Hamed Khorsand

  • ECVT has experienced a series of block trades over the past year after its largest shareholder decided to liquidate its position.
  • The block sales overshadow the second quarter that is expected to show a rebound in ECVT’s ecoservices
  • For second quarter 2023 we are raising our sales and adjusted EBITDA estimate

Immix Biopharma – ATM completion may extend runway into H224

By Edison Investment Research

Immix Biopharma has completed its $5.0m at-the-market (ATM) offering program. The funding is as a result of the initial share sales agreement in March 2023 and is anticipated to further support Immix’s pipeline activities with the development of its key assets: the CAR-T treatment, NXC-201, and the tissue-specific therapeutic, IMX-110. We view the ATM offering as a positive, especially in light of the current macro funding environment for biotech companies.


Kimberly-Clark: Short-Term Tailwinds, But Little Hope For The Long Run

By Vladimir Dimitrov, CFA

  • Kimberly-Clark’s disappointing performance in recent years is hardly a surprise and does not make the company a bargain.
  • The short-term perspective on margins remains mixed, in spite of the management’s optimism.
  • KMB could no longer support these activities, according to the company’s management.

Applied Materials Inc.: Launch of New R&D Facility & Other Drivers

By Baptista Research

  • Applied Materials managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.
  • Despite weaknesses in consumer electronics, the company sees robust demand driven by technology inflections and regional supply chain investments.
  • Applied Materials noted that leading-edge foundry logic customers have adjusted their spending plans but remain committed to their long-term roadmaps.

Marvell Technology Inc.: Launch Of Silicon Interconnects A Possible Game Changer? – Key Drivers

By Baptista Research

  • Marvell managed to exceed analyst expectations in terms of revenue as well as earnings.
  • The company sees significant opportunities in the AI sector, as AI data centers require high-capacity, low-latency connectivity, driving demand for Marvell’s PAM4 optical DSP platform.
  • Marvell expects the AI trend to continue growing, with plans to double revenue in fiscal 2024 and at least double it again in fiscal 2025.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars